Jasper Therapeutics, Inc. 2Q 2026: Net loss $(2.8M), EPS $(0.10) — 10-Q SummaryTradingView·Aug 14 at 10:11 AMJSPR+6.59%
Jasper Therapeutics Q2 FY26 net loss narrows to $2.76 million; R&D expense drops to $5.14 millionPUBT·Aug 14 at 10:00 AMJSPR+6.59%KPRX+1.57%
Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update | JSPR Stock NewsStockTitan·Aug 14 at 02:00 AMJSPR+6.59%
U.S. stock market quick update: JSPR down 9.07%! Analysts support KP-104, why is the market not buying it?Price Alert·Aug 12 at 02:44 PMJSPR+6.59%
Inside the Under-the-Radar Reshuffle Across Tech and Defensive AssetsGlobal Report·Aug 12 at 05:12 AMCLBT-6.28%VERI-5.65%
Biren Amin Initiates Buy on Jasper Therapeutics, Highlighting KP-104’s Differentiated Dual-Pathway Mechanism and $1.5B Peak Sales Potential in Kidney DiseasesTip Ranks·Aug 12 at 04:45 AMJSPR+6.59%
Jasper Therapeutics holds annual stockholders meeting; 75% of shares representedPUBT·Aug 3 at 03:55 PMJSPR+6.59%
Macro Signals Across the Microstructure: What a Diverse Basket Says About Capital FlowsGlobal Report·Jul 30 at 04:13 AMWMB-2.33%EWBC-0.79%
Capital Reallocation on the Fringes: Signals of Strategic PivotsGlobal Report·Jul 26 at 04:14 AMGNRC+0.89%BWEN-2.04%
The Fragmentation of Innovation: Why Niche Markets Matter This SummerGlobal Report·Jul 25 at 04:13 AMSTDN0.00%CAPR+12.03%
